Evidence map›Paper›PMID 25288773›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Mapping of transcription factor motifs in active chromatin identifies IRF5 as key regulator in classical Hodgkin lymphoma.

Stephan Kreher, M Amine Bouhlel, Pierre Cauchy, Björn Lamprecht, Shuang Li, Michael Grau, Franziska Hummel, Karl Köchert, Ioannis Anagnostopoulos, Korinna Jöhrens and 16 more

Open access · greenAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 55 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
  11. Sequences to Differences in Gene Expression: Analysis of RNA-Seq Data.Methods in molecular biology (Clifton, N.J.) · 2022
    Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors at 10 institutions in 4 countries.

Stephan KreherMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
M Amine BouhlelLeeds Institute of Molecular Medicine, University of Leeds, Leeds LS9 7TF, United Kingdom;
Pierre CauchySchool of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom;
Björn LamprechtMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;
Shuang LiMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Michael GrauDepartment of Physics, Philipps University, 35052 Marburg, Germany;
Franziska HummelMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Karl KöchertMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Ioannis AnagnostopoulosInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany;
Korinna JöhrensInstitute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany;
Michael HummelGerman Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; Institute of Pathology, Charité-Universitätsmedizin Berlin, 10117 Berlin, Germany;
John HiscottVaccine and Gene Therapy Institute of Florida, Port St. Lucie, FL 34987;
Sören-Sebastian WenzelHematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Peter LenzDepartment of Physics, Philipps University, 35052 Marburg, Germany;
Markus SchneiderInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122 Essen, Germany;
Ralf KüppersInstitute of Cell Biology (Cancer Research), University of Duisburg-Essen, 45122 Essen, Germany;
Claus ScheidereitMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany;
Maciej GiefingInstitute of Human Genetics, Christian-Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany; and Institute of Human Genetics, Polish Academy of Sciences, 60-479 Poznan, Poland.
Reiner SiebertInstitute of Human Genetics, Christian-Albrechts University Kiel and University Hospital Schleswig-Holstein, Campus Kiel, 24105 Kiel, Germany; and.
Klaus RajewskyMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany;
Georg LenzHematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Peter N CockerillSchool of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom;
Martin JanzMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany;
Bernd DörkenMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany;
Constanze BoniferSchool of Cancer Sciences, College of Medical and Dental Sciences, University of Birmingham, Birmingham B15 2TT, United Kingdom; c.bonifer@bham.ac.uk stephan.mathas@charite.de.
Stephan MathasMax-Delbrück-Center for Molecular Medicine, 13125 Berlin, Germany; Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, 13353 Berlin, Germany; German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany; c.bonifer@bham.ac.uk stephan.mathas@charite.de.
Charité - Universitätsmedizin Berlin · DEMax Delbrück Center · DEUniversity of Birmingham · GBHeidelberg University · DEPhilipps University of Marburg · DEUniversity of Duisburg-Essen · DEUniversity Hospital Schleswig-Holstein · DEUniversity of Leeds · GBUniversity of Lübeck · DEVaccine & Gene Therapy Institute of Florida · US

Funding

Cancer Research UK
6 · The paper itself

Abstract

Deregulated transcription factor (TF) activities are commonly observed in hematopoietic malignancies. Understanding tumorigenesis therefore requires determining the function and hierarchical role of individual TFs. To identify TFs central to lymphomagenesis, we identified lymphoma type-specific accessible chromatin by global mapping of DNaseI hypersensitive sites and analyzed enriched TF-binding motifs in these regions. Applying this unbiased approach to classical Hodgkin lymphoma (HL), a common B-cell-derived lymphoma with a complex pattern of deregulated TFs, we discovered interferon regulatory factor (IRF) sites among the top enriched motifs. High-level expression of the proinflammatory TF IRF5 was specific to HL cells and crucial for their survival. Furthermore, IRF5 initiated a regulatory cascade in human non-Hodgkin B-cell lines and primary murine B cells by inducing the TF AP-1 and cooperating with NF-κB to activate essential characteristic features of HL. Our strategy efficiently identified a lymphoma type-specific key regulator and uncovered a tumor promoting role of IRF5.

Indexed as

Amino Acid MotifsAnimalsB-LymphocytesCell LineageCell Line, TumorChemokinesChemotaxisChromatinCytokinesDeoxyribonuclease IGene Expression ProfilingGene Expression Regulation, NeoplasticHodgkin DiseaseHumansInflammationInterferon Regulatory FactorsChemokinesChromatinCytokinesDeoxyribonuclease IInterferon Regulatory FactorsIRF5 protein, humanNF-kappa BTranscription Factor AP-1

Identifiers

PMID25288773
PMCPMC4210307
OpenAlexW2155249898

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.